-
Mashup Score: 16Risk of major bleeding in recurrent fallers receiving anticoagulation for atrial fibrillation: a prospective cohort study - 13 day(s) ago
The risk of fall-related bleeding is a frequent reason for not following recommendations on anticoagulation in patients with atrial fibrillation (AF).
Source: www.rpthjournal.orgCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 8Relevance of anti-PF4/H antibodies and platelet activation in systemic inflammatory diseases and thrombosis disorders: insight from the COVID-19 pandemic - 4 month(s) ago
The increased interest in anti-platelet factor 4 (PF4)-heparin complex (anti-PF4/H) antibodies following the COVID-19 pandemic has established them as crucial players in immunothrombosis. We aimed to investigate the involvement of anti-PF4/H antibodies during COVID-19 and after vaccination, particularly in patients with systemic inflammatory disease (SID).
Source: www.rpthjournal.orgCategories: General Medicine News, Hem/OncsTweet-
🥳New findings from our group on anti-PF4/H antibodies during #COVID19 and post #vaccination ! #HIT #VITT @RPTHjournal 📰 🔗https://t.co/jBVcAkLOGX @ThalerMd28725 @DorotheeFaille @RichardChocron @TerrierBen @DavidMSmadja
-
-
Mashup Score: 4A call to action: MTHFR polymorphisms should not be a part of inherited thrombophilia testing - 5 month(s) ago
Testing for polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene is still a standard part of thrombophilia testing in many laboratories. However, it is clear that these polymorphisms are not risk factors for arterial or venous thrombosis and therefore should not be part of thrombophilia testing. Eliminating MTHFR from thrombophilia testing will reduce patient concerns and health care costs.
Source: www.rpthjournal.orgCategories: General Medicine News, Hem/OncsTweet-
A call to action: MTHFR polymorphisms should not be a part of inherited thrombophilia testing [Jun 8, 2022] @Bloodman et al. The WTD Steering Committee - @RPTHjournal https://t.co/iPnkg8MJhm #VTE https://t.co/2uwdmNQKEv
-
-
Mashup Score: 19Andexanet alfa: trials just leave us with more questions - 5 month(s) ago
ANNEXA-I, the first ever randomised controlled trial of a reversal agent for direct oral anticoagulants, was published in 2024. The trial, which randomised patients with intracranial haemorrhage to andexanet alfa or usual care was mandated by the Federal Drugs Administration as part of its conditional approval in 2018, an approval that was originally based on the single-arm trial, ANNEXA-4. ANNEXA-I was stopped early for benefit and showed a reduction in the number of patients with significant haematoma expansion.
Source: www.rpthjournal.orgCategories: General Medicine News, Hem/OncsTweet-
RT @richardbuka: Pleased to share this perspective on andexanet alfa, now published in @RPTHjournal #openaccess🔓 https://t.co/pl1myt01oI I…
-
-
Mashup Score: 17Andexanet alfa: trials just leave us with more questions - 5 month(s) ago
ANNEXA-I, the first ever randomised controlled trial of a reversal agent for direct oral anticoagulants, was published in 2024. The trial, which randomised patients with intracranial haemorrhage to andexanet alfa or usual care was mandated by the Federal Drugs Administration as part of its conditional approval in 2018, an approval that was originally based on the single-arm trial, ANNEXA-4. ANNEXA-I was stopped early for benefit and showed a reduction in the number of patients with significant haematoma expansion.
Source: www.rpthjournal.orgCategories: General Medicine News, Hem/OncsTweet-
RT @richardbuka: Pleased to share this perspective on andexanet alfa, now published in @RPTHjournal #openaccess🔓 https://t.co/pl1myt01oI I…
-
-
Mashup Score: 113Hormonal therapies and venous thrombosis: Considerations for prevention and management - 5 month(s) ago
Venous thromboses are well‐established complications of hormonal therapy. Thrombosis risk is seen with both hormonal contraceptive agents and with hormone replacement therapy for menopause and gender transition. Over the past several decades, large epidemiological studies have helped better define these risks.
Source: www.rpthjournal.orgCategories: General Medicine News, Hem/OncsTweet-
Awesome paper on hormonal therapies, thrombosis, and what to do about it! @Bloodman to the rescue Hormonal therapies and venous thrombosis: Considerations for prevention and management - Research and Practice in Thrombosis and Haemostasis https://t.co/45tLLmsi0Q
-
-
Mashup Score: 3Characterization of bleeding in thrombotic thrombocytopenic purpura in the precaplacizumab era: a retrospective nationwide analysis - 6 month(s) ago
The addition of caplacizumab to immune thrombotic thrombocytopenia (iTTP) treatment options has led to a renewed interest in characterizing the epidemiology and risk factors for bleeding in iTTP. Limited data exist on the bleeding risk in iTTP due to systemic underreporting in earlier cohorts.
Source: www.rpthjournal.orgCategories: General Medicine News, Hem/OncsTweet-
Out now: https://t.co/YKPr7tsWvy
-
-
Mashup Score: 2Type of D-dimer assay determines the diagnostic yield of Computed Tomography in patients suspected for pulmonary embolism - 7 month(s) ago
Pulmonary embolism (PE) is a life-threatening condition with high morbidity and mortality. The diagnosis of PE is challenging due to nonspecific symptoms, making reliable diagnostic tools essential. This study addresses the clinical impact of inter-assay variability in D-dimer measurements on the utilization and diagnostic yield of computed tomography pulmonary angiography (CTPA).
Source: www.rpthjournal.orgCategories: General Medicine News, Hem/OncsTweet-
🤓 Type of D-dimer assay determines the diagnostic yield of CTPA in patients suspected for PE - @RPTHjournal ➡️Hospitals using the Roche Tinaquant assay ordered 21% fewer CTPAs and had an 7% higher positivity rate compared to those using the Siemens https://t.co/vIcVHJ3VUU
-
-
Mashup Score: 4Comorbidity and adverse events in acquired hemophilia A: data from the GTH-AHA-EMI study - 7 month(s) ago
Persons with acquired hemophilia A are often older and suffer from comorbidity or frailty. Little is known about the impact on clinically relevant outcomes of acquired hemophilia A.
Source: www.rpthjournal.orgCategories: General Medicine News, Oncologists1Tweet-
Comorbidity and adverse events in acquired hemophilia A: data from the GTH-AHA-EMI study @RPTHjournal https://t.co/EXGrrG8tPp
-
-
Mashup Score: 11Distinguishing hyperfibrinolysis from enhanced–fibrinolytic-type disseminated intravascular coagulation - 8 month(s) ago
We read with interest the article by Taylor et al. [1] describing the laboratory tests, treatment, and course of a hyperfibrinolytic condition during the treatment of rhabdomyosarcoma. The authors stated that bleeding during the treatment of rhabdomyosarcoma was due to hyperfibrinolysis, a condition that should be distinguished from disseminated intravascular coagulation (DIC). However, that case was thought to represent DIC with abnormally enhanced fibrinolysis, so-called enhanced–fibrinolytic-type DIC [2].
Source: www.rpthjournal.orgCategories: General Medicine News, Oncologists1Tweet-
Distinguishing hyperfibrinolysis from enhanced–fibrinolytic-type disseminated intravascular coagulation @RPTHjournal https://t.co/LPcYQglZIX
-
More data it’s ok to anticoagulate people at risk of falls: Risk of major bleeding in recurrent fallers receiving anticoagulation for atrial fibrillation: a prospective cohort study @tony_breu https://t.co/liGucaGEPH